State Street’s Corbus Pharmaceuticals CRBP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.39M | Buy |
254,672
+185,800
| +270% | +$1.76M | ﹤0.01% | 3279 |
|
|
2026
Q1 | $647K | Buy |
68,872
+13,780
| +25% | +$116K | ﹤0.01% | 3594 |
|
|
2025
Q4 | $448K | Hold |
55,092
| – | – | ﹤0.01% | 3708 |
|
|
2025
Q3 | $697K | Hold |
55,092
| – | – | ﹤0.01% | 3592 |
|
|
2025
Q2 | $380K | Sell |
55,092
-168,378
| -75% | -$1.22M | ﹤0.01% | 3677 |
|
|
2025
Q1 | $1.19M | Sell |
223,470
-5,130
| -2% | -$45.3K | ﹤0.01% | 3392 |
|
|
2024
Q4 | $2.7M | Sell |
228,600
-366,976
| -62% | -$6.15M | ﹤0.01% | 3215 |
|
|
2024
Q3 | $12.3M | Buy |
595,576
+153,243
| +35% | +$7.84M | ﹤0.01% | 2487 |
|
|
2024
Q2 | $20M | Buy |
442,333
+406,354
| +1,129% | +$17.1M | ﹤0.01% | 2174 |
|
|
2024
Q1 | $1.41M | Buy |
35,979
+22,800
| +173% | +$562K | ﹤0.01% | 3385 |
|
|
2023
Q4 | $79.6K | Hold |
13,179
| – | – | ﹤0.01% | 4099 |
|
|
2023
Q3 | $88.8K | Hold |
13,179
| – | – | ﹤0.01% | 4137 |
|
|
2023
Q2 | $103K | Hold |
13,179
| – | – | ﹤0.01% | 4231 |
|
|
2023
Q1 | $95.8K | Sell |
13,179
-5
| -0% | -$22 | ﹤0.01% | 4336 |
|
|
2022
Q4 | $43.7K | Hold |
13,184
| – | – | ﹤0.01% | 4588 |
|
|
2022
Q3 | $65K | Hold |
13,184
| – | – | ﹤0.01% | 4594 |
|
|
2022
Q2 | $100K | Hold |
13,184
| – | – | ﹤0.01% | 4535 |
|
|
2022
Q1 | $210K | Buy |
13,184
+1,277
| +11% | +$16.9K | ﹤0.01% | 4364 |
|
|
2021
Q4 | $220K | Hold |
11,907
| – | – | ﹤0.01% | 4310 |
|
|
2021
Q3 | $364K | Buy |
11,907
+150
| +1% | +$5.92K | ﹤0.01% | 4102 |
|
|
2021
Q2 | $645K | Sell |
11,757
-39,904
| -77% | -$2.21M | ﹤0.01% | 3769 |
|
|
2021
Q1 | $3.05M | Buy |
51,661
+7,209
| +16% | +$474K | ﹤0.01% | 3261 |
|
|
2020
Q4 | $1.67M | Sell |
44,452
-509,486
| -92% | -$19M | ﹤0.01% | 3428 |
|
|
2020
Q3 | $29.9M | Buy |
553,938
+452,402
| +446% | +$81.9M | ﹤0.01% | 1796 |
|
|
2020
Q2 | $25.6M | Buy |
101,536
+62,982
| +163% | +$12.7M | ﹤0.01% | 1896 |
|
|
2020
Q1 | $6.06M | Buy |
38,554
+1,165
| +3% | +$197K | ﹤0.01% | 2530 |
|
|
2019
Q4 | $6.12M | Buy |
37,389
+739
| +2% | +$109K | ﹤0.01% | 2755 |
|
|
2019
Q3 | $5.36M | Buy |
36,650
+1,951
| +6% | +$340K | ﹤0.01% | 2753 |
|
|
2019
Q2 | $7.21M | Buy |
34,699
+3,644
| +12% | +$780K | ﹤0.01% | 2640 |
|
|
2019
Q1 | $6.47M | Buy |
31,055
+1,584
| +5% | +$349K | ﹤0.01% | 2639 |
|
|
2018
Q4 | $5.16M | Buy |
29,471
+391
| +1% | +$78K | ﹤0.01% | 2693 |
|
|
2018
Q3 | $6.59M | Buy |
29,080
+2,481
| +9% | +$401K | ﹤0.01% | 2729 |
|
|
2018
Q2 | $4.03M | Buy |
26,599
+27
| +0.1% | +$4.91K | ﹤0.01% | 2969 |
|
|
2018
Q1 | $4.86M | Buy |
26,572
+3,143
| +13% | +$706K | ﹤0.01% | 2811 |
|
|
2017
Q4 | $4.99M | Buy |
23,429
+1,235
| +6% | +$264K | ﹤0.01% | 2796 |
|
|
2017
Q3 | $4.76M | Buy |
22,194
+2,572
| +13% | +$503K | ﹤0.01% | 2823 |
|
|
2017
Q2 | $3.71M | Buy |
19,622
+18,989
| +3,000% | +$3.72M | ﹤0.01% | 2880 |
|
|
2017
Q1 | $156K | Sell |
633
-14
| -2% | -$3.44K | ﹤0.01% | 3519 |
|
|
2016
Q4 | $164K | Hold |
647
| – | – | ﹤0.01% | 3511 |
|
|
2016
Q3 | $132K | Buy |
+647
| New | +$80.5K | ﹤0.01% | 3429 |
|
Other funds holding CRBP
CAM
O
JHC
PM
SCM
ACM
State Street's CRBP Position: Q2 2026 in Review
State Street increased its Corbus Pharmaceuticals (CRBP) stake by 270% in Q2 2026, buying an estimated $1.76M and bringing the position to 254,672 shares worth $2.39M. The position accounts for ﹤0.01% of the portfolio, ranked #3279.
State Street first reported a position in CRBP in Q3 2016 and has held it in 40 quarters since. The position peaked at $29.9M in Q3 2020. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.
- State Street held 254,672 shares of Corbus Pharmaceuticals worth $2.39M as of Q2 2026.
- State Street bought 185,800 Corbus Pharmaceuticals shares in Q2 2026, an estimated $1.76M.
- Corbus Pharmaceuticals made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3279 holding.
- State Street first reported a position in Corbus Pharmaceuticals in Q3 2016 and has held it in 40 quarters since.
- State Street's Corbus Pharmaceuticals position peaked at $29.9M in Q3 2020.
- 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.
Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.